Natália dos Santos Gonçalves
Research Subjects
Research Interests
Natália dos Santos Gonçalves has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Barcelos Ribeiro
University of Franca, Franca, Brazil
1 shared publication - Carlos Henrique Inacio Ramos
Institute of Chemistry, State University of Campinas, Campinas, SP, Brazil
1 shared publication - Cassia Suemi Mizuno
College of Pharmacy and Health Sciences Western New England University Springfield Massachusetts USA
1 shared publication - Heber Eduardo Andrada
Universidade de Franca , Av. Dr Armando Salles Oliveira 201
1 shared publication - Julia Mirian Paulino
Department of Exact and Technological Sciences Research, University of Franca, Av. Dr. Armando de Sáles Oliveira, 201, Parque Universitario, Franca 14404-600, SP, Brazil
1 shared publication - Raquel Alves dos Santos
Universidade de Franca
1 shared publication
Latest Publications
- 7 October 2025
- Published by Taylor & Francis in Natural Product Research
- p. 1-8
p53 mediates the cellular responses to cis -trimethoxystilbene in breast cancer cell lines
The present study investigated the cellular inhibitory effects of cis-trimethoxystilbene (cis-TMS) on the chemoresistant MDA-MB-231 breast cancer cell line and the role of p53 in mediating the cellular responses to this compound. Treatment with cis-TMS significantly inhibited the growth of MDA-MB-231 cells, reducing the cell viability by approximately 75% at 2.5 µM and increasing apoptosis rates to nearly 20%. Silencing p53 in MCF-10A and MCF-7 cell lines revealed that cis-TMS-induced apoptosis and cell cycle arrest were p53-dependent. The interaction studies suggest that cis-TMS does not alter the conformation of p53 at low concentrations but may influence its activity at higher doses. The results suggest that cis-TMS selectively targets cancer cells with functional p53, offering a potential targeted therapy approach. However, the reliance on p53 and the risk of genomic instability pose limitations, requiring further research to optimise the therapeutic strategies involving cis-TMS.
- 7 October 2025
- Published by Taylor & Francis in Natural Product Research
- p. 1-8
p53 mediates the cellular responses to cis -trimethoxystilbene in breast cancer cell lines
The present study investigated the cellular inhibitory effects of cis-trimethoxystilbene (cis-TMS) on the chemoresistant MDA-MB-231 breast cancer cell line and the role of p53 in mediating the cellular responses to this compound. Treatment with cis-TMS significantly inhibited the growth of MDA-MB-231 cells, reducing the cell viability by approximately 75% at 2.5 µM and increasing apoptosis rates to nearly 20%. Silencing p53 in MCF-10A and MCF-7 cell lines revealed that cis-TMS-induced apoptosis and cell cycle arrest were p53-dependent. The interaction studies suggest that cis-TMS does not alter the conformation of p53 at low concentrations but may influence its activity at higher doses. The results suggest that cis-TMS selectively targets cancer cells with functional p53, offering a potential targeted therapy approach. However, the reliance on p53 and the risk of genomic instability pose limitations, requiring further research to optimise the therapeutic strategies involving cis-TMS.